What side effects are common with Pluvicto (lutetium Lu 177 vipivotide tetraxetan)?
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a targeted radiation therapy used for certain men with metastatic castration-resistant prostate cancer. Across clinical use, side effects most often relate to radiation effects on normal tissues and the effect on bone marrow.
Commonly reported side effects include:
- Low blood counts (especially anemia, low platelets, and low white blood cells), which can increase fatigue, bleeding/bruising risk, and infection risk [1][2]
- Nausea, vomiting, and decreased appetite [1]
- Dry mouth and constipation or diarrhea [1]
- Fatigue/weakness [1]
- Kidney-related effects such as changes in creatinine or other lab markers, which can reflect kidney radiation exposure [1][2]
What serious risks should patients watch for?
Patients and clinicians focus closely on blood-count complications and radiation-related organ effects.
Key serious risks include:
- Myelosuppression: clinically significant anemia, neutropenia, or thrombocytopenia that may require treatment delays, dose adjustments, or supportive care [1][2]
- Infections: higher risk when white blood cells are low [1][2]
- Kidney injury: radiation exposure can affect kidney function in some patients; monitoring kidney labs is part of routine care [1][2]
- Gastrointestinal toxicity: severe nausea/vomiting, dehydration, or electrolyte problems can occur, especially if supportive meds are inadequate [1]
How does Pluvicto compare with other prostate cancer therapies in side-effect patterns?
Pluvicto’s profile differs from hormone therapy and chemotherapy because it delivers targeted radiation to prostate cancer cells.
Compared with treatments like chemotherapy (which commonly causes neuropathy and hair loss), Pluvicto tends to be more associated with:
- Blood-count suppression from radiation to bone marrow
- Kidney lab changes
- Less typical systemic chemotherapy effects
That said, overlap can happen: for example, patients may already be anemic from advanced cancer before starting Pluvicto, which can make treatment-related anemia harder to distinguish.
Do side effects get worse with each cycle?
For many patients, blood-count suppression can become more noticeable over successive cycles, because each treatment adds radiation exposure. Kidney function changes can also be cumulative in some cases.
Clinicians typically use lab monitoring (blood counts and kidney function) to decide whether a patient needs:
- Treatment delays
- Dose modifications
- Additional supportive medicines (for example, to manage low counts) [1][2]
What does monitoring usually involve during treatment?
Because Pluvicto affects the blood and can affect kidneys, routine monitoring commonly includes:
- Complete blood counts to track anemia, neutropenia, and thrombocytopenia [1][2]
- Kidney function tests (lab-based monitoring of creatinine and related measures) [1][2]
- Symptom checks (fatigue, nausea/vomiting, infection symptoms) at each visit [1]
What side effects lead to stopping or delaying Pluvicto?
Treatment is often delayed or adjusted if a patient develops:
- Severe or worsening low blood counts (myelosuppression) [1][2]
- Significant decline in kidney function or kidney-related lab changes [1][2]
- Severe gastrointestinal symptoms that do not improve with supportive care [1]
The specific threshold depends on the prescribing guidance and the patient’s baseline labs.
Are there drugs or supportive treatments used to reduce side effects?
Supportive care commonly includes anti-nausea medicines and proactive monitoring for blood-count issues. Depending on the patient’s risk and baseline labs, clinicians may also use additional supportive therapies for low counts.
When should a patient seek urgent medical care?
Patients should contact their oncology team promptly, and seek urgent care if they have signs of complications such as:
- Fever or chills (possible infection with low white blood cells) [1][2]
- Uncontrolled vomiting, severe weakness, or signs of dehydration [1]
- Easy bruising or unusual bleeding (possible thrombocytopenia) [1][2]
---
Sources
[1] https://www.drugs.com/monograph/pluvicto.html
[2] https://www.drugpatentwatch.com/p/pluvicto